Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Cornea and External Disease > Two Studies Show the Economic Impact of Infectious Conjunctivitis
  • Cornea and External Disease

Two Studies Show the Economic Impact of Infectious Conjunctivitis

Ophthalmology 360
Two Studies Show the Economic Impact of Infectious Conjunctivitis

Infective conjunctivitis was shown to cause economic burden in two posters presented by Jay Stuart Prepose MD, PhD, of the Prepose Vision Institute in Chesterfield, MO, during the American Academy of Ophthalmology’s 2018 annual meeting in Chicago.

In the first study, investigators found that family health care costs increased with each new family member infected, as well as with increased transmission time. Researchers used the Optum Healthcare Solutions database to estimate total conjunctivitis episode costs, including the cost of care in seed patients and infected family members. Overall, nearly 900,000 seed patients experienced ~1.1 million episodes. Among the results:

  • Cost per episode in those who did not transmit to a family member was ~$800.
  • When family members were infected, costs increased more than $450/infected family member.
  • Longer time of transmission between seed patient and family member also increased costs – from ~$140 when the transmission period was between 1 and 7 days, to nearly $200 when it was greater than 7 days.
  • Total direct costs were more than $40 lower in seed patients who received conjunctivitis medication on the day they were diagnosed.

In the second study, Dr. Prepose found that conjunctivitis can lead to notable financial burden, including medically-related absenteeism. He and his colleagues used the Optum database to identify individuals with (n=~1 million) and without (n=~4.9 million) conjunctivitis. They compared direct and indirect costs over 2 months following diagnosis of conjunctivitis (or 2 months after an assigned date in those without the infection).  Among the results:

  • Emergency room visits were nearly $16 higher on average in patients with conjunctivitis.
  • Outpatient visits were ~$64 higher, and pharmacy costs were ~$26 higher.
  • Medically-related absenteeism was more than $100 higher in patients with conjunctivitis.

Prepose J, Cheung H, Bobbili P, Joseph C, Du M. Impact of infectious conjunctivitis transmission in families on direct all-cause health-care costs: A U.S. claims analysis. Poster presented at: AAO 2018 annual meeting; October, 26-30, 2018; Chicago.

Prepose J, Cheung H, Bobbili P, Joseph C, Du M. Direct and indirect costs of infectious conjunctivitis in the general population: A U.S. claims analysis. Poster presented at: AAO 2018 annual meeting; October, 26-30, 2018; Chicago.

Share

Related Content

  • Cornea and External Disease

Quiz: The impact of blepharitis and conjunctivitis on quality of life

  • Cornea and External Disease

Phase 3 trial of cenegermin-bkbj for PCED enrolls first US patient

  • Cornea and External Disease

Cornea specialists identify key clinical signs linked to microbial keratitis subtypes

Cornea Update: Corneal Dystrophies & Related Conditions with an Update on Genetic Assessment and Treatment
  • Cornea and External Disease

Preventing complications of superficial keratectomy

  • Glaucoma

Review finds low adverse event rates for glaucoma stents

  • Retina

Switching to aflibercept 8 mg extends treatment intervals in suboptimal nARMD responders

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon